Calfactant for Direct Acute Respiratory Distress Syndrome

PHASE3TerminatedINTERVENTIONAL
Enrollment

332

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

December 31, 2010

Study Completion Date

February 28, 2011

Conditions
Respiratory Distress Syndrome, Adult
Interventions
DRUG

Calfactant

Intratracheal Instillation of 0.5 mL/cm of height of 60 mg/mL suspension in two aliquots at study entry. Repeat dosing 12 hours later if criteria are met.

DRUG

Room Air (placebo)

Administration of 0.5 ml/cm height of air at study entry into the trachea. Repeat dosing at 12 hours if criteria are met

Trial Locations (32)

22908

University of Virginia Health Science Center, Charlottesville

68131

Creighton University, Omaha

68198

Omaha Children's Hospital, Omaha

Unknown

University of Florida, Gainesville

Florida Hospital and Florida Children's Hospital, Orlando

Northwestern University-Chicago, Chicago

West Suburban Hospital Medical Center, Oak Park

Peoria Pulmonary Associates/OSF St. Francis Hospital, Peoria

Clarian Health, Inc/Methodist Hospital, Indianapolis

University of Iowa, Iowa City

Dartmouth-Hitchcock Medical Center, Lebanon

Columbia Medical Center--Pediatrics, New York

The Oregon Clinic, Portland

Penn State University, Hershey

Baylor College of Medicine/Texas Children's Hospital, Houston

Uthscsa/Stvah, San Antonio

INOVA Fairfax Hospital, Fairfax

Medical College of Wisconsin, Milwaukee

Royal Adelaide Hospital, Adelaide

Royal Columbian Hospital, New Westminster

British Columbia Children's Hospital, Vancouver

Surrey Memorial Hospital, Vancouver

Vancouver General Hospital, Vancouver

Kingston General Hospital, Kingston

London Health Sciences Centre, London

Ottawa Hospital, Ottawa

Haemek Medical Center, Jerusalem

Rabin Medical Center, Jerusalem

Auckland City Hospital, Auckland

Starship Children's Hospital, Auckland

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Pneuma Pharmaceuticals Incorporated

OTHER